April is the deadline. May could be the rollback. SAMHSA's OTP rule and the H.R. 5629 fight, explained.
Opioid treatment programs are racing to comply with new federal flexibilities — while Congress debates a bill that would erase them.
April is the deadline. May could be the rollback. SAMHSA’s OTP rule and the H.R. 5629 fight, explained.
This month marks the first hard compliance deadline for the most significant update to U.S. opioid treatment program (OTP) regulation in more than twenty years. The SAMHSA final rule, published in February 2024 in the Federal Register, raises the maximum initial methadone dose from 30 mg to 50 mg (important for patients with high fentanyl tolerance), makes COVID-era take-home flexibilities permanent (up to 28 days after the first month of treatment), and integrates harm reduction principles into routine OTP practice — including naloxone distribution and fentanyl/xylazine test strip access.
At the same time, the House Energy and Commerce Subcommittee on Health is reviewing H.R. 5629, which would nullify the rule. The Pew Charitable Trusts submitted testimony on April 7 arguing that the bill would erase three specific gains: expanded take-home methadone in early treatment, telehealth-based admission for methadone and buprenorphine, and dose-splitting flexibility for high-acuity patients. Pew cites studies showing these flexibilities reduced travel burden and kept people in treatment without measurable increases in diversion.
Why this matters for people in recovery
The practical impact lands at the program level: every OTP in Arizona is operationally restructuring this month to meet the new rule. If H.R. 5629 advances, some of those same programs will have to restructure again. For patients, the simplest takeaway is to ask your program directly about take-home eligibility and telehealth options — both are explicitly preserved under current federal law as of today, but the policy environment is shifting in real time.
Sources Cited
- 01.B
- 02.B
- 03.B
- 04.B
Filed Under
policytreatmentSAMHSA
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
The Overdose Numbers Are Falling. Cocaine Is the Exception Nobody's Toasting.
CDC data show overdose deaths falling nationally, but stimulant-only deaths are rising, and Medicaid coverage for the one treatment that works, contingency management, remains rare.
Policy & FundingSAMHSA Killed Funding for Fentanyl Test Strips. Then CDC Bragged About Falling Overdose Deaths.
SAMHSA cut federal funding for fentanyl test strips and syringes in April. Five months later, CDC's new overdose dashboard shows deaths falling 12.3% — and harm reduction groups in Kentucky, Ohio, and South Carolina are the ones absorbing the contradiction.
Policy & FundingDEA Drew a Real Line on Kratom. Whether It Holds Isn't Decided Yet.
The federal comment period on DEA's proposed 0.05% threshold for 7-hydroxymitragynine closed September 10, 2026. Here's the real state of kratom scheduling right now — and what it doesn't change.